

## Press Release

## El.En.: Cynosure Receives FDA 510(k) Clearance for Cellulaze Cellulite Laser Workstation

## World's First Minimally Invasive Aesthetic Device for Cellulite Reduction Platform

Florence, January 30th, 2012– El.En. S.p.A., leader on the laser market and listed on the STAR segment of the Italian Stock Exchange, reports that its controlled company Cynosure, Inc. (NASDAQ: CYNO, of which El.En. retains control by the ownership of 23% of the shares) today announced that the U.S. Food and Drug Administration has cleared the Company's Cellulaze™ Workstation for commercial distribution.

Nearly four years of clinical research puts Cellulaze in a class of its own: the only single-treatment aesthetic procedure clinically shown to reduce cellulite. Cellulaze also complements other body shaping technologies, such as the Smartlipo<sup>TM</sup> family of workstations.

"Cellulaze is the world's first and only minimally invasive medical device designed to treat women who have struggled to eliminate cellulite through diet and exercise, or have tried the myriad of lotions and creams currently on the market," said Cynosure President and Chief Executive Officer Michael Davin. "Unlike those products, Cellulaze is the only aesthetic device that directly treats the physiological structure of cellulite, providing clinically proven, results."

An estimated 85% of women over the age of 20 have some form of cellulite – pockets of fat deposited just beneath the surface of the skin, around the hips, thighs, and buttocks, which produces an "orange-peel" or a "cottage cheese" appearance. The treatment of cellulite is a multibillion-dollar industry, according to market estimates.



El.En., an Italian company, is the parent company of a high-.tech industrial group operating in the optoelectronics sector. Based on proprietary technology and multidisciplinary know-how, the El.En Group manufactures laser sources (gas, semiconductor, solid-state and liquid) and innovative laser systems for medical and industrial applications. The El.En. Group is the laser market leader in Italy and among the top operators in Europe. It designs, manufactures and sells worldwide:

- Medical laser equipment used in dermatology, cosmetics, physiotherapy, dentistry and gynecology;
- Industrial laser systems for applications ranging from cutting, marking and welding metals, wood, plastic and glass to decorating leather and textiles and restoring/conserving artwork;
- Laser systems for scientific research

EL.EN is listed on the Star (MTAX) of Borsa Italiana. Its market floatation is approximately 47% and its market capitalization amounts to  $\epsilon$  51 millions of euro.

Cod. ISIN: IT0001481867

Code: ELN Listed on MTA

Mkt capt.: 51 mln/Euro Cod. Reuters: ELN.MI Cod. Bloomberg: ELN IM

For further information:

EI.En. SpA Enrico ROMAGNOLI Investor Relations Tel. +39-055-8826807 finance@elen.it Polytems HI R Roberta Mazzeo Press Office Tel. +39/066797849–06 69923324 r.mazzeo@polytemshir.it Polytems HIR
Bianca FERSINI MASTELLONI
Financial Communication
Tel. +39/066797849-06 69923324
b.fersini@polytemshir.it